Evidence map›Paper›PMID 16827897›Full record

ArticleImmunology2006

The fate of effector CD8 T cells in vivo is controlled by the duration of antigen stimulation.

Xiaopei Huang, Yiping Yang

Abstract read
In one paragraph

Article in Immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. In situ vaccine, immunological memory and cancer cure.Human vaccines & immunotherapeutics · 2016
    Article
  5. Allospecific CD4(+) effector memory T cells do not induce graft-versus-host disease in mice.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaopei HuangDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Yiping Yang

Funding

THERAPEUTIC APPROACHES TO OVARIAN/BREAST CANCER--HIGH DOSE CHEMOTHERAPY AND ABMSP01CA047741 · NCI · DUKE UNIVERSITY · PI CHAO, NELSON J. · 1990 to 2013
$19.5M
Immunotherapy for Epstein-Barr Virus-associated MalignanK22CA093659 · NCI · DUKE UNIVERSITY · PI YANG, YIPING · 2002 to 2004
$457k
NCI NIH HHS CA047741NCI NIH HHS CA093659NCI NIH HHS K22 CA093659NCI NIH HHS P01 CA047741
6 · The paper itself

Abstract

What controls the fate of the T-cell response remains incompletely defined. Gain of effector function facilitated by costimulation has been thought to be a crucial factor in determining the outcome of the T-cell response, i.e. long-term memory in the presence of costimulation versus tolerance induction in the absence of costimulation. In this study, we show that while costimulation or cognate CD4 helps to promote the acquisition of effector function during the initial phase of the CD8 T-cell response, the fate of effector CD8 T cells is controlled by the duration of subsequent antigenic stimulation. Effector CD8 T cells differentiate into memory cells only after clearance of antigen, whereas in the presence of persistent antigen, effector CD8 T cells are tolerized. Furthermore, protective immunity against tumour cannot develop in the persisting antigen environment. These results suggest that removal of persisting antigen by other means might be a prerequisite for effective immunotherapy in cancer.

Indexed as

Adoptive TransferAnimalsAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationCells, CulturedCytotoxicity, ImmunologicHemagglutinins, ViralImmune ToleranceImmunologic MemoryLymphocyte CooperationLymphomaMiceMice, Inbred StrainsMice, TransgenicAntigens, ViralHemagglutinins, Viral

Identifiers

PMID16827897
PMCPMC1782300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.